Effect of agomelatine in the chronic mild stress model of depression in the rat

Neuropsychopharmacology

Volumn 28, Issue 4, 2003, Pages 694-703

  Papp, Mariusz ^a   Gruca, Piotr ^a   Boyer, Pierre Alain ^b   Mocaer, Elisabeth ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT2C receptors; Agomelatine; Antidepressant; Chronic mild stress; Circadian; Melatonin; Rat

Indexed keywords

ACETAMIDE DERIVATIVE; AGOMELATINE; ANTIDEPRESSANT AGENT; CELL RECEPTOR; CELL SURFACE RECEPTOR; MELATONIN RECEPTOR; SEROTONIN 1C RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL; ARTICLE; CHRONIC DISEASE; CHRONOTHERAPY; COMPARATIVE STUDY; DEPRESSION; DISEASE MODEL; DRUG POTENTIATION; MALE; METHODOLOGY; PHYSIOLOGY; RAT; STRESS; WISTAR RAT;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CHRONOTHERAPY; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; RECEPTORS, SEROTONIN; STRESS;

EID: 0038050606     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300091     Document Type: Article

References (44)

1. Armstrong SM, Mcnulty OM, Guardiola-Lemaitre B, Redman JR (1993).Successful use of S 20098 and melatonin in an animalmodel of delayed sleep-phase syndrome.PharmacolBiochemBehav46: 45-49.
2. Beck-Friis J, Ljunggren JG, Thorsen M, Van Rosen JG, Kjellman BK, Wetterberg L (1985). Melatonin, cortisol and ACTH inpatients with major depressive disorder and healthy humanswith special reference to the outcome of the dexamethasonesuppression test.Psychoneuroendocrinology10: 173-186.
3. Bonnefond C, Martinet L, Lesieur D, Adam G, Guardiola-Lemaitre B (1993).Characterization of S-20098, a new melatoninanalogue. In: Touitou Y, Arendt J, Pevet P (eds).Melatoninand the Pineal Gland.Elsevier Science Publishers: Amsterdam.pp 123-126.
4. Brogden RN, Heel RC, Speight TM, Avery GS (1978).Mianserin: a review of its pharmacological properties and therapeutic efficacyin depressive illness.Drugs16: 273-301.
5. Brown RP, Koccis JH, Caroff S, Amsterdam J, Winokar A, Stekes P (1985).Difference in nocturnal melatonin secretion betweenmelancholic depressed patients and control subjects.Am JPsychiatry142: 811-816.
6. Cheeta S, Ruigt G, van Proosdij J, Willner P (1997). Changes in sleep architecture following chronic mild stress.Biol Psychiatry41: 419-427.
7. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G (1984). A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biological marker in major depression.Biol Psychiatry19: 1215-1228.
8. Conway S, Canning SJ, Edward Howell HH, Mowat ES, Barrett P, Drew JE et al(2000). Characterizations of human mt1/MT2receptors by CRE-luciferase reporter assay.Eur J Pharmacol390:15-24.
9. Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ (2002).Antagonist properties of the melatonin agonist S 20098(agomelatine) at recombinant, human (h) serotonin (5-HT2c), receptors.Int J Neuropsychopharmacol 5(Suppl 1): S68.
10. Dahl K, Avery DH, Lewy AJ, Savage MV, Brengelmann GL, Larsen L et al(1993). Dim light melatonin onset and circadiantemperature during a constant routine in hypersomnic winterdepression.ActaPsychiatrScand88: 60-66.
11. D’Aquila P, Newton J, Willner P (1997).Diurnal variation in the effect of chronic mild stress on sucrose intake and preference.PhysiolBehav62: 421-426.
12. De Ridder JJ (1982). Mianserin: a result of a decade of antidepressant research.Pharm WeekblSci22: 139-145.
13. Gorka Z, Moryl E, Papp M (1996). Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats.PharmacolBiochemBehav54: 229-234.
14. Healy D (1993). Dysphoria. In: Costelloe G (ed).The Symptoms of Depression. Wiley and Sons: Chichester. pp 24-45.
15. Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R (1999). The effects of melatonin on the behavioural disturbances inducedby chronic mild stress in C3H/He mice.BehavPharmacol10: 7383.
16. Lewy AJ, Sack RL, Miller LS, Hoban TM (1987).Antidepressant and circadian phase-shifting effects of light.Science235: 352-354.
17. Martinet L, Guardiola-Lemaitre B, Mocaer E (1996). Entrainment of circadian rhythms by S 20098 a melatonin agonist is dose andplasma concentration dependent.PharmacolBiochemBehav54:713-718.
18. Montgomery S (1980).Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients.Neuropharmacology19: 1185-1190.
19. Moreau J-L, Scherschlict R, Jenck F, Martin JR (1995). Chronic mild stress-induced anhedonia model of depression: sleepabnormalities and curative effects of electroshock treatment.BehavPharmacol6: 682-687.
20. Muscat R, Papp M, Willner P (1992).Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine andmaprotiline.Psychopharmacology109: 433-438.
21. Overstreet DH, Pucilowski O, Retton MC, Delagrange P, Guardiola-Lemaitre B (1998).Effect of melatonin receptor ligands on swim test immobility.Neuroreport9: 249-253.
22. Papp M, Sanchez C (2002). Escitalopram has potent and rapid effect in a chronic mild stress model of depression in rats.BiolPsychiatry51: 68S.
23. Raghavendra V, Kaur G, Kulkarni SK (2000). Antidepressant action of melatonin in chronic forced swimming-inducedbehavioral despair in mice, role of peripheral benzodiazepinereceptor modulation.EurNeuropsychopharmacol10: 473-481.
24. Redman JR, Francis AJP (1998). Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intactsuprachiasmatic nuclei but not the pineal.J Biol Rhythms13:39-51.
25. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM (1995). Dose-dependent effects of S 20098, amelatonin agonist on direction of reentrainment of rat circadianrhythms.Psychopharmacology118: 385-390.
26. Rubin RT, Heist EK, McGeoy SS, Hanada K, Lesser IM (1992).Neuroendocrine aspects of primary endogenous depression.Arch Gen Psychiatry49: 558-567.
27. Sack RL, Lewy AJ, White DM, Singer CM, Fireman MJ, Vandiver R (1990). Morning vs evening light therapy for winter depression: evidence that the therapeutic effects of light are mediated by circadian phase shifting.Arch Gen Psychiatry47: 343-351.
28. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake ofbiogenic amines and on receptor binding.Cell MolNeurobiol19: 467-489.
29. Sekula LK, Lucke JF, Heist EK, Czmbel RK, Rubin RT (1997). Neuroendocrine aspects of primary endogenous depression.Psychiatr Res24: 143-153.
30. Shaji AV, Kulkarni SK (1998).Central nervous system depressant activities of melatonin in rats and mice.Ind J ExpBiol36: 257-263.
31. Souetre E, Salvati E, Belugou JL, Candito M, Krebs B, Ardisson JL et al(1989). Circadian rhythms in depression and recovery:evidence for blunted amplitude as the main chronobiologicalabnormality.Psychiatr Res28: 263-278.
32. Strauss WH, Klieser E (1991). Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.EurNeuropsychophar-macol1: 101-105.
33. Szymanska A, Rabe-Jablonska J, Karasek M (2001). Diurnal profile of melatonin concentrations in patients with major depression:relationship to the clinical manifestation and antidepressanttreatment.NeuroendocrinolLett22: 192-198.
34. Thompson C, Franey C, Arendt J, Checkley SA (1988). A comparison of melatonin secretion in depressed patients andnormal subjects.Br J Psychiatry152: 260-265.
35. Van Reeth O, Olivares Y, Zhang FW, Turek FW, Defrance R, Mocaer E (1997). Comparative effects of a melatonin agonist onthe circadian system in mice and syrian hamsters.Brain Res762:185-194.
36. Van Reeth O, Weibel L, Olivares E, Maccari S, Mocaer E, Turek FW (2001). Melatonin or a melatonin agonist correct age-relatedchanges in circadian response to an environmental stimulus.AmJ Physiol280: 1582-1591.
37. Wehr TA, Wirz-Justice A (1982). Circadian rhythm mechanisms in affective illness and in antidepressant drug action.Pharmacop-sychiatry15: 31-39.
38. Weibel L, Turek FW, Mocaeer E, Van Reeth O (2000). A melatonin agonist facilitates circadian clock resynchronization in oldhamsters after abrupt shifts in the light-dark cycle.Brain Res880: 207-211.
39. Weibel L, Rettori MC, Lesieur D, Delagrange P, Renard P, Van Reeth O (1999). A single oral dose of S 22153, a melatoninantagonist, blocks the phase advancing effects of melatonin inC3H mice.Brain Res829: 160-166.
40. Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10 years review and evaluation.Psychopharmacology134: 319-329.
41. Ying SW, Rusak B, Delagrange P, Mocaer E, Renard P, Guardiola-Lemaitre B (1996). Melatonin analogues as agonist and antagonists in the circadian system and other brain areas.EurJ Pharmacol296: 33-42.
42. Ying SW, Rusak B, Mocaer E (1998). Chronic exposure to melatonin receptor agonists does not alter their effects onsuprachiasmatic nucleus neurons.Eur J Pharmacol342: 29-37.
43. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B et al(1992). Novel naphthalenic ligands with high affinity for themelatonin receptor.J Med Chem35: 1484-1486.
44. Zetin M, Potkin S, Urbanchek M (1987). Melatonin in depression.Psychiatr Ann17: 676-681.